|LE Magazine November 1999 |
The Life Extension Foundation regularly profiles and evaluates important new products on the market, often making them available directly to you, as well as to Foundation members at a discount via the Life Extension Buyers Club.
The Word Is Out!
News of s-adenosylmethionine (SAMe) hit the newsstands earlier this year, when the March 22, 1999 issue of Newsweek magazine introduced this European therapy to readers nationwide. Interestingly, although not surprisingly, Foundation members first learned about SAMe in 1996.
Used throughout Europe as a dietary supplement that has been clinically shown to promote joint health and emotional well-being, SAMe is a natural form of bioactive methionine. It is considered a "methyl donor," as it contributes a methyl group to help other molecules become active.
The scientific literature shows that s-adenosylmethionine (SAMe) is an exceedingly safe and effective depression therapy. SAMe has also been shown to be useful in the treatment of osteoarthritis, fibromyalgia, and liver cirrhosis. Furthermore, recent reports reveal that SAMe may also be involved in the prevention of Alzheimer's disease and even aging itself. How? Cellular aging is partially caused by de-methylation. SAMe facilitates enzymatic activity throughout the body by enhancing DNA re-methylation. Since SAMe re-methylates DNA, it has enormous potential as an anti-aging agent.
Now, the secrets of SAMe are available in a bottle. Thanks to a new stabilization process, The Foundation is now able to offer SAMe in bottles that contain fifty 200 mg tablets, offering convenience to those who prefer tablets in a bottle rather than blister-packs in a box. Either way, SAMe does its job. Whether you choose SAMe to stabilize moods, treat arthritis, fibromyalgia or cirrhosis, or use it as ananti-aging agent, SAMe is now more accessible than ever before. Take it from the Europeans, SAMe does work!
Back to the Magazine Forum